Myricx Bio wins Cancer Research Horizons Start-Up Achievement Award

We are delighted to share that Myricx Bio has been awarded the 2025 Start-Up Achievement Recognition Award by Cancer Research Horizons.

The Myricx team was honoured to attend the Cancer Research Horizons Innovation and Entrepreneurship Awards Dinner, on 10^th July 2025 at Merchant Taylors’ Hall in London. The event brought together leading scientists and companies making real-world impact for cancer patients. Myricx Bio, co-founded by Ed Tate in 2019, was recognised for its pioneering work in developing a novel class of antibody-drug conjugates (ADCs) using proprietary N-myristoyltransferase inhibitors (NMTi) as a new payload modality. Over the past two years, the company has demonstrated that NMTi-ADCs can achieve complete and durable tumour regressions at well-tolerated doses in multiple preclinical models of solid cancer.

Following a £90 million ($114 million) Series A financing in 2024, Myricx has expanded its leadership and R&D teams and moved into dedicated laboratories in London. The nomination of a lead development candidate this year marks a major milestone on the path to becoming a clinical-stage company in 2026.

Receiving the award on the evening were Ed Tate, Julie Mead, Francesca Zammarchi, and Jesper Valbjørn.

Photo credit: Greg Allen